<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS132549</article-id>
<article-id pub-id-type="doi">10.1101/2021.08.06.455494</article-id>
<article-id pub-id-type="archive">PPR380417</article-id>
<article-version article-version-type="publisher-id">2</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lo</surname>
<given-names>Michael K.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="corresp" rid="CR1">*#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shrivastava-Ranjan</surname>
<given-names>Punya</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chatterjee</surname>
<given-names>Payel</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flint</surname>
<given-names>Mike</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beadle</surname>
<given-names>James R.</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Valiaeva</surname>
<given-names>Nadejda</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schooley</surname>
<given-names>Robert T.</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hostetler</surname>
<given-names>Karl Y.</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Montgomery</surname>
<given-names>Joel M.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Spiropoulou</surname>
<given-names>Christina</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>a</label>Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, Georgia, USA</aff>
<aff id="A2">
<label>b</label>Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, USA</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Address correspondence to: #Michael K. Lo: <email>mko2@cdc.gov</email> and Christina F. Spiropoulou: <email>ccs8@cdc.gov</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>08</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>10</day>
<month>08</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>Ebola virus</kwd>
<kwd>Nipah virus</kwd>
<kwd>respiratory viruses</kwd>
<kwd>hemorrhagic fever virus</kwd>
<kwd>filovirus</kwd>
<kwd>paramyxovirus</kwd>
<kwd>henipavirus</kwd>
<kwd>Remdesivir</kwd>
<kwd>GS-5734</kwd>
<kwd>Remdesivir nucleoside</kwd>
<kwd>GS-441524</kwd>
<kwd>antiviral agents</kwd>
<kwd>lipid prodrugs</kwd>
<kwd>ODBG</kwd>
<kwd>Vero E6 cells</kwd>
<kwd>Huh7 cells</kwd>
<kwd>NCI-H358 cells</kwd>
<kwd>human telomerase reverse-transcriptase (hTERT) immortalized microvascular endothelial cells (TIME)</kwd>
<kwd>and human small airway epithelial cells (HSAEC1-KT)</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p id="P2">Remdesivir (RDV; Veklury, GS-5734) is an adenosine nucleotide analog phosphoramidate prodrug with broad-spectrum antiviral activity in vitro and in vivo (<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R8">8</xref>), and is currently the only therapeutic approved by the FDA for treating coronavirus 19 disease (COVID-19) in hospitalized patients over the age of 12 (<xref ref-type="bibr" rid="R9">9</xref>). While RDV did not significantly reduce COVID-19 mortality, it did shorten the time to recovery compared to a placebo control group (<xref ref-type="bibr" rid="R10">10</xref>). The short half-life of RDV in human and animal plasma (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R12">12</xref>), alongside the in vivo efficacy of RDV parent nucleoside (GS-441524, RVn) against coronaviruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R16">16</xref>), have driven proposals to utilize RVn instead of RDV to treat COVID-19 (<xref ref-type="bibr" rid="R17">17</xref>). A recent comparative pharmacokinetic study in non-human primates, however, demonstrated higher nucleoside triphosphate (NTP) levels in lower respiratory tract tissues of RDV-dosed animals than in RVn-dosed animals (<xref ref-type="bibr" rid="R8">8</xref>). A significant drawback of RDV is the requirement for intravenous administration, which limits its use to hospital contexts. In an attempt to develop an orally bioavailable form of remdesivir, we recently synthesized a 1-O-octadecyl-2-O-benzyl-sn-glycerylester (ODBG) lipid-modified monophosphate prodrug of RVn (ODBG-P-RVn), which demonstrated more favorable in vitro antiviral activity against SARS-CoV-2 compared to that of RVn and RDV in Vero-E6 cells (<xref ref-type="bibr" rid="R18">18</xref>).</p>
<p id="P3">In this study, we extended our in vitro comparisons to include 14 viruses from across 7 virus families responsible for causing diseases of significant human public health concern. These were <italic>Filoviridae</italic>: Ebola virus (EBOV) and Marburg virus (MARV) (<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R20">20</xref>); <italic>Paramyxoviridae</italic>: Nipah virus (NiV), Hendra virus (HeV), human parainfluenza virus 3 (hPIV3), measles virus (MV), mumps virus (MuV), and Sosuga virus (SoSuV) (<xref ref-type="bibr" rid="R21">21</xref>–<xref ref-type="bibr" rid="R27">27</xref>); <italic>Pneumoviridae</italic>: respiratory syncytial virus (RSV) (<xref ref-type="bibr" rid="R28">28</xref>); <italic>Flaviviridae</italic>: yellow fever virus (YFV); <italic>Arenaviridae</italic>: Lassa virus (LASV) (<xref ref-type="bibr" rid="R29">29</xref>); <italic>Nairoviridae</italic>: Crimean-Congo hemorrhagic fever virus (CCHFV) (<xref ref-type="bibr" rid="R30">30</xref>); and <italic>Coronaviridae</italic>: SARS-CoV-2 (<xref ref-type="bibr" rid="R31">31</xref>). We utilized 3 previously described assays to compare the antiviral activities of RVn, RDV, and ODBG-P-RVn against this panel of viruses: 1) directly measuring fluorescence of a reporter protein expressed by recombinant viruses (REP) (<xref ref-type="bibr" rid="R2">2</xref>), (<xref ref-type="fig" rid="F1">Figure 1A</xref>); 2) quantitating focus-forming units (FFU) via fluorescent reporter imaging (<xref ref-type="bibr" rid="R32">32</xref>) (<xref ref-type="fig" rid="F1">Figure 1B</xref>); and 3) indirectly measuring cytopathic effect (CPE) based on cellular ATP levels (CellTiterGlo 2.0, Promega) (<xref ref-type="bibr" rid="R2">2</xref>) (<xref ref-type="fig" rid="F1">Figure 1C</xref>), which was also used to evaluate compound cytotoxicity (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Assay conditions varied based on virus replication kinetics and on the specific assay used; multiplicities of infection (MOI) ranged from 0.01–0.25, and endpoint measurements were conducted between 72-144 hours post-infection (hpi). We initially conducted dose-response experiments using 8-point, 3-fold serial dilutions of RVn, RDV, and ODBG-P-RVn against our panel of viruses in Vero-E6 cells, and showed that ODBG-P-RVn consistently had greater antiviral activity than RVn and RDV against all viruses susceptible to RVn/RDV inhibition, with effective concentration (EC<sub>50</sub>) values ranging from 0.026 to 1.13 μM (<xref ref-type="fig" rid="F1">Figure 1</xref>, Vero-E6 assays represented in left column of panels A, B, C; Supplemental <xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>; <xref ref-type="table" rid="T1">Table 1</xref>). RVn and ODBG-P-RVn induced partial cytotoxicity but only at the highest concentration tested (100 μM) and without reaching 50% cytotoxicity (CC<sub>50</sub>). We then compared these antivirals in human hepatoma (Huh7) and bronchioalveolar carcinoma (NCI-H358) cell lines, which represent more relevant cell types targeted by subsets of viruses used in our study. In both human cell lines, although ODBG-P-RVn showed EC<sub>50</sub> values remarkably similar to those observed in Vero-E6 cells and was 3- to 5-fold more active than RVn, it consistently showed 6- to 20-fold less activity than RDV (<xref ref-type="fig" rid="F1">Figure 1</xref> [Huh7 and NCI-H358 assays represented, respectively, in the middle and right columns of panels A, B, and C]; Supplemental <xref ref-type="supplementary-material" rid="SD1">Figures S2</xref>, <xref ref-type="supplementary-material" rid="SD1">S3</xref>; <xref ref-type="table" rid="T1">Table 1</xref>). Whereas CC<sub>50</sub> values for RDV in Huh7 and NCI-H358 cells were 54.2 and 77.2 μM, respectively, ODBG-P-RVn was less cytotoxic in Huh7 cells (CC<sub>50</sub> = 93.4 μM) and did not show measurable cytotoxicity in NCI-H358 cells even at the highest concentration tested (100 μM) (<xref ref-type="fig" rid="F1">Figure 1D</xref>, right panel; <xref ref-type="table" rid="T1">Table 1</xref>).</p>
<p id="P4">To further evaluate cell type-specific effects on the antiviral activities of RVn, RDV, and ODBG-P-RVn, we tested them against a smaller subset of filoviruses (EBOV-ZsG, MARV-ZsG) and a paramyxovirus (NiV-ZsG) expressing ZsGreen reporter in primary-like human telomerase reverse transcriptase (hTERT) immortalized human microvascular endothelial (TIME) cells (<xref ref-type="bibr" rid="R33">33</xref>, <xref ref-type="bibr" rid="R34">34</xref>). In TIME cells, we observed a similar trend in antiviral activity as in Huh7 and NCI-H358 cells, with ODBG-P-RVn showing 15- to 22-fold greater activity than RVn, but 5- to 8-fold less activity than RDV in reporter-based assays (<xref ref-type="fig" rid="F2">Figure 2A</xref>, <xref ref-type="table" rid="T2">Table 2</xref>). To confirm this, we compared the respective abilities of RDV and ODBG-P-RVn to reduce infectious yield of EBOV-ZsG and NiV-ZsG (MOI = 0.25) when cells were treated with each compound 2 hpi. Virus supernatants were collected at 72hpi and titered on Huh7 (for EBOV-ZsG) or NCI-H358 (for NiV-ZsG) cells to determine 50% tissue culture infectious dose (TCID<sub>50</sub>) by the method of Reed and Muench (<xref ref-type="bibr" rid="R35">35</xref>). Both RDV and ODBG-P-RVn equivalently reduced infectious yield of EBOV-ZsG by up to 4 log<sub>10</sub> and of NiV-ZsG by approximately 2 log<sub>10</sub>, in a dose-dependent manner, with EC<sub>50</sub> values closely mirroring values determined in reporter assays (<xref ref-type="fig" rid="F2">Figure 2B</xref>, left and middle panels; <xref ref-type="table" rid="T2">Table 2</xref>). However, RDV was more cytotoxic (CC<sub>50</sub> = 17.2 μM) than ODBG-P-RVn (CC<sub>50</sub> &gt; 50 μM) (<xref ref-type="fig" rid="F2">Figure 2B</xref>, right panel; <xref ref-type="table" rid="T2">Table 2</xref>), which is reflected in its biphasic inhibition of NiV-ZsG (<xref ref-type="fig" rid="F2">Figure 2B</xref>, middle panel, cytotoxic inhibition by RDV shown at 16.6 μM). Since the ODBG lipid modification has been shown to enhance in vivo lung tissue distribution for a different orally administered nucleoside (<xref ref-type="bibr" rid="R36">36</xref>), we compared the activity of the 3 compounds against filoviruses, paramyxoviruses, and RSV in another primary-like, hTERT-immortalized small airway epithelial cell (HSAEC1-KT) (<xref ref-type="bibr" rid="R37">37</xref>). Notably, the dose-response curves of RDV and ODBG-P-RVn were strikingly similar, with EC<sub>50</sub> values in the submicromolar range within a 3-fold range of each other; EC<sub>50</sub> values for some viruses were almost identical (<xref ref-type="fig" rid="F2">Figure 2C</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 4</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). Furthermore, RDV and ODBG-P-RVn equivalently reduced the infectious yields of EBOV-ZsG and NiV-ZsG in HSAEC1-KT cells by by 5 log<sub>10</sub> and 3 log<sub>10</sub>, respectively, and their EC<sub>50</sub> values reflected the limited differential in antiviral activity between them (<xref ref-type="fig" rid="F2">Figure 2D</xref>, left and middle panels; <xref ref-type="table" rid="T2">Table 2</xref>). Although ODBG-P-RVn was more cytotoxic (CC<sub>50</sub> = 20.5) in HSAEC1-KT cells than RDV (CC<sub>50</sub> &gt; 100; <xref ref-type="fig" rid="F2">Figure 2D</xref>, right panel; <xref ref-type="table" rid="T2">Table 2</xref>), it also effectively reduced virus yields at non-cytotoxic concentrations.</p>
<p id="P5">In summary, our results demonstrate that ODBG-P-RVn has greater antiviral activity than RVn in all cell lines tested and has cell-type dependent activity levels that range from moderately lesser than to nearly equal to those of RDV. <italic>In vivo</italic> RDV is converted rapidly to RVn (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R12">12</xref>), which has 0.5 to 2 log<sub>10</sub> less activity than RDV against most of the viruses tested. In contrast, ODBG-P-RVn is stable in plasma for &gt;24 hours and at therapeutic plasma levels of ODBG-P-Rvn (above EC<sub>90</sub> for SARS-CoV-2) after oral administration of 16.9 mg/kg to Syrian hamsters; furthermore RVn was not observed at virologically significant levels (<xref ref-type="bibr" rid="R38">38</xref>). Thus, one would predict sustained <italic>in vivo</italic> antiviral activity with ODBG-P-RVn without substantial generation in plasma of RVn, the less active metabolite. Taken together, our results strongly support investigation of in vivo efficacy of ODBG-P-RVn not only against SARS-CoV-2 but also against other viruses significant to human health.</p>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplemental Figures</label>
<media xlink:href="EMS132549-supplement-Supplemental_Figures.pdf" mimetype="application" mime-subtype="pdf" id="N66206" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S1">
<title>Acknowledgments</title>
<p>We thank Tatyana Klimova for helpful comments in reviewing the manuscript. We thank Pei-Yong Shi (University of Texas Medical Branch) for the kind gift of the reporter SARS-CoV-2 expressing mNeonGreen. The findings and conclusions in this report are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. This work was supported by CDC core funding and by the National Institute of Allergy and Infectious Diseases (RO1-AI131424).</p>
</ack>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warren</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Mackman</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Soloveva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Perron</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bannister</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>
<article-title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</article-title>
<source>Nature</source>
<year>2016</year>
<volume>531</volume>
<fpage>381</fpage>
<lpage>5</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Arvey</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sudhamsu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shrivastava-Ranjan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hotard</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McMullan</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Mackman</surname>
<given-names>RL</given-names>
</name>
<etal/>
</person-group>
<article-title>GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses</article-title>
<source>Sci Rep</source>
<year>2017</year>
<volume>7</volume>
<elocation-id>43395</elocation-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheahan</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Pyre</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Trantcheva</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bannister</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title>
<source>Sci Transl Med</source>
<year>2017</year>
<volume>9</volume>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Feldmann</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gary</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bannister</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cronin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Klena</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Cihlar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zaki</surname>
<given-names>SR</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge</article-title>
<source>Sci Transl Med</source>
<year>2019</year>
<volume>11</volume>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Wit</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Feldmann</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cronin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Okumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cihlar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Feldmann</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1073/pnas.1922083117</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pruijssers</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>George</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Gralinksi</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Dinnon</surname>
<given-names>KH</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Yount</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Agostini</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Chappell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice</article-title>
<source>Cell Rep</source>
<year>2020</year>
<volume>32</volume>
<elocation-id>107940</elocation-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheahan</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Hogg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Babusis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Spahn</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group>
<article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<fpage>222</fpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackman</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Perron</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Palmiotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stray</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Byun</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Prodrugs of a 113-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV</article-title>
<source>Journal of Medicinal Chemistry</source>
<year>2021</year>
<volume>64</volume>
<fpage>5001</fpage>
<lpage>5017</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="web">
<collab>Gilead</collab>
<year>2020</year>
<date-in-citation>Accessed 07/08/2021</date-in-citation>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.veklury.com/">https://www.veklury.com/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beigel</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Tomashek</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Zingman</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Kalil</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Hohmann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Luetkemeyer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kline</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lopez de Castilla</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir for the Treatment of Covid-19 — Final Report</article-title>
<source>New England Journal of Medicine</source>
<year>2020</year>
<volume>383</volume>
<fpage>1813</fpage>
<lpage>1826</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>TempestiHi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Caputi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Avataneo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Notari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Forini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Scorzolini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marchioni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ascoli Bartoli</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Castilletti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lalle</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Capobianchi</surname>
<given-names>MR</given-names>
</name>
<etal/>
</person-group>
<article-title>Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19</article-title>
<source>J Antimicrob Chemother</source>
<year>2020</year>
<volume>75</volume>
<fpage>2977</fpage>
<lpage>2980</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Humeniuk</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mathias</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Osinusi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chng</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>German</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects</article-title>
<source>Clin Transl Sci</source>
<year>2020</year>
<volume>13</volume>
<fpage>896</fpage>
<lpage>906</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shuai</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>ZF</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract</article-title>
<source>Emerging Microbes &amp; Infections</source>
<year>2021</year>
<volume>10</volume>
<fpage>481</fpage>
<lpage>492</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models</article-title>
<source>J Med Chem</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.Oc01929</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Perron</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Eckstrand</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liepnieks</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>NC</given-names>
</name>
</person-group>
<article-title>The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies</article-title>
<source>Vet Microbiol</source>
<year>2018</year>
<volume>219</volume>
<fpage>226</fpage>
<lpage>233</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedersen</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Perron</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bannasch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Liepnieks</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis</article-title>
<source>J Feline Med Surg</source>
<year>2019</year>
<volume>21</volume>
<fpage>271</fpage>
<lpage>281</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>VMF</given-names>
</name>
</person-group>
<article-title>Comprehensive Summary Supporting Clinical Investigation of GS-441524 for Covid-19 Treatment</article-title>
<year>2020</year>
<comment>doi:10.31219, OSFPREPRINTS</comment>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schooley</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Carlin</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Beadle</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Valiaeva</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XQ</given-names>
</name>
<name>
<surname>Garretson</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>VI</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hostetler</surname>
<given-names>KY</given-names>
</name>
</person-group>
<article-title>Rethinking Remdesivir: Synthesis of Lipid Prodrugs that Substantially Enhance Anti-Coronavirus Activity</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.08.26.269159</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albarino</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Wiggleton Guerrero</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Towner</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein</article-title>
<source>Virology</source>
<year>2015</year>
<volume>484</volume>
<fpage>259</fpage>
<lpage>64</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Deval</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Spiropoulou</surname>
<given-names>CF</given-names>
</name>
</person-group>
<article-title>Susceptibility of paramyxoviruses and filoviruses to inhibition by 2’-monofluoro-and 2’-difluoro-4’-azidocytidine analogs</article-title>
<source>Antiviral Res</source>
<year>2018</year>
<volume>153</volume>
<fpage>101</fpage>
<lpage>113</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bukreyev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>Cl</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Peeples</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Pickles</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium</article-title>
<source>J Virol</source>
<year>2005</year>
<volume>79</volume>
<fpage>1113</fpage>
<lpage>24</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Spiropoulou</surname>
<given-names>CF</given-names>
</name>
</person-group>
<article-title>Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening</article-title>
<source>Antiviral Res</source>
<year>2014</year>
<volume>106</volume>
<fpage>53</fpage>
<lpage>60</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rennick</surname>
<given-names>U</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Carsillo</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Lemon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>van Amerongen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ludlow</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Yuksel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Verburgh</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Haddock</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McQuaid</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates</article-title>
<source>J Virol</source>
<year>2015</year>
<volume>89</volume>
<fpage>2192</fpage>
<lpage>200</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rota</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>He</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Rescue of wild-type mumps virus from a strain associated with recent outbreaks helps to define the role of the SH ORF in the pathogenesis of mumps virus</article-title>
<source>Virology</source>
<year>2011</year>
<volume>417</volume>
<fpage>126</fpage>
<lpage>136</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welch</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Wiggleton Guerrero</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jenks</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Spiropoulou</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Albariño</surname>
<given-names>CG</given-names>
</name>
</person-group>
<article-title>Development of a reverse genetics system for Sosuga virus allows rapid screening of antiviral compounds</article-title>
<source>PLoS neglected tropical diseases</source>
<year>2018</year>
<volume>12</volume>
<elocation-id>e0006326-e0006326</elocation-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Selleck</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hyatt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gleeson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Westbury</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hiley</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Selvey</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rodwell</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>A morbillivirus that caused fatal disease in horses and humans</article-title>
<source>Science</source>
<year>1995</year>
<volume>268</volume>
<fpage>94</fpage>
<lpage>7</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harcourt</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tamin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Bankamp</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bowden</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rollin</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Comer</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ksiazek</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Hossain</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Gurley</surname>
<given-names>ES</given-names>
</name>
<etal/>
</person-group>
<article-title>Genetic characterization of Nipah virus, Bangladesh, 2004</article-title>
<source>Emerg Infect Dis</source>
<year>2005</year>
<volume>11</volume>
<fpage>1594</fpage>
<lpage>7</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallak</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Spillmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Peeples</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection</article-title>
<source>J Virol</source>
<year>2000</year>
<volume>74</volume>
<fpage>10508</fpage>
<lpage>13</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welch</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Guerrero</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>McMullan</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bluemling</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Painter</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Spiropoulou</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Albarino</surname>
<given-names>CG</given-names>
</name>
</person-group>
<article-title>Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems</article-title>
<source>Antiviral Res</source>
<year>2016</year>
<volume>136</volume>
<fpage>9</fpage>
<lpage>18</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welch</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Scholte</surname>
<given-names>FEM</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Bergeron</surname>
<given-names>É</given-names>
</name>
<name>
<surname>Spiropoulou</surname>
<given-names>CF</given-names>
</name>
</person-group>
<article-title>Identification of 2l3-deoxy-2l3-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus</article-title>
<source>Antiviral Research</source>
<year>2017</year>
<volume>147</volume>
<fpage>91</fpage>
<lpage>99</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Muruato</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lokugamage</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Narayanan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schindewolf</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bopp</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Aguilar</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Plante</surname>
<given-names>KS</given-names>
</name>
<etal/>
</person-group>
<article-title>An Infectious cDNA Clone of SARS-CoV-2</article-title>
<source>Cell Host Microbe</source>
<year>2020</year>
<volume>27</volume>
<fpage>841</fpage>
<lpage>848</lpage>
<elocation-id>e3</elocation-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Amblard</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kasthuri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bassit</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schinazi</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Nichol</surname>
<given-names>ST</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent in vitro activity of β-D-413-chloromethyl-2lĩ]-deoxy-213-fluorocytidine against Nipah virus</article-title>
<source>Antiviral Research</source>
<year>2020</year>
<volume>175</volume>
<elocation-id>104712</elocation-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Doerffler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Neville</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carra</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lew</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<etal/>
</person-group>
<article-title>Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,l-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses</article-title>
<source>J Med Chem</source>
<year>2017</year>
<volume>60</volume>
<fpage>1648</fpage>
<lpage>1661</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venetsanakos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mirza</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fanton</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Romanov</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Tlsty</surname>
<given-names>T</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells</article-title>
<source>Exp Cell Res</source>
<year>2002</year>
<volume>273</volume>
<fpage>21</fpage>
<lpage>33</lpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reed</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Muench</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A simple method of estimating fifty percent endpoints</article-title>
<source>Am J Hygiene</source>
<year>1938</year>
<volume>27</volume>
<fpage>493</fpage>
<lpage>497</lpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hostetler</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Beadle</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Trahan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aldern</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schriewer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Melman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Buller</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice</article-title>
<source>Antiviral Res</source>
<year>2007</year>
<volume>73</volume>
<fpage>212</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramirez</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Sheridan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pollack</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peyton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kurie</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Dimaio</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Milchgrub</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins</article-title>
<source>Cancer Res</source>
<year>2004</year>
<volume>64</volume>
<fpage>9027</fpage>
<lpage>34</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schooley</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Carlin</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Beadle</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Valiaeva</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X-Q</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>McMillan</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Leibel</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>McVicar</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Garretson</surname>
<given-names>AF</given-names>
</name>
<etal/>
</person-group>
<article-title>Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs</article-title>
<source>Antimicrobial Agents and Chemotherapy</source>
<year>2021</year>
<volume>0</volume>
<elocation-id>AAC.01155-21</elocation-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in African green monkey (Vero-E6), human hepatoma (Huh7), and human bronchioalveolar carcinoma (NCI-H358) cell lines using reporter-based, image-based, and cytopathic effect (CPE) assays. Representative dose-response inhibition of viral replication and induction of cellular cytotoxicity by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). A) Direct measurement of reporter fluorescence intensity by recombinant Ebola virus (EBOV) expressing ZsGreen protein in Vero-E6 (left panel) and Huh7 (middle panel) cells, and recombinant Nipah virus (NiV) expressing ZsGreen protein in NCI-H358 (right panel) cells. B) Image-based counting of reporter fluorescence-positive cells infected with recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) expressing mNeonGreen protein (Vero-E6 and Huh7) and recombinant respiratory syncytial virus (RSV) expressing eGFP (NCI-H358). Infected cells treated with DMSO were considered as 100% fluorescence intensity signal and 100% fluorescence-positive cell counts. C) Compound-based inhibition of CPE induced by yellow fever virus (YFV) in Vero-E6 and Huh7 cells and by Hendra virus (HeV) in NCI-H358 cells determined by measuring cellular ATP levels (CellTiterGlo 2.0). ATP levels in uninfected cells treated with DMSO were considered 100% CPE inhibition. D) Compound cytotoxicity/cell viability measured by CellTiterGlo 2.0 assay. Dose-response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point, 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate. RVn and RDV used in this study was obtained from MedChemExpress (Monmouth Junction, NJ USA).</p>
</caption>
<graphic xlink:href="EMS132549-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Comparison of cell type-dependent antiviral activities of RVn, RDV, and ODBG-P-RVn in primary-like hTERT-immortalized microvascular endothelial (TIME) cells and small airway epithelial cells (HSAEC1-KT).</title>
<p>A) Representative dose-response inhibition of recombinant EBOV, NiV, and Marburg virus (MARV) expressing ZsGreen protein in TIME cells. B) Yield reduction of infectious EBOV-ZsG (left panel) and NiV-ZsG (middle panel) by RDV and ODBG-P-RVn. Compound cytotoxicity/cell viability (right panel) in TIME cells measured via CellTiterGlo 2.0 assay. C) Representative dose-response inhibition of recombinant EBOV, NiV, and MARV expressing ZsGreen protein in HSAEC1-KT cells. D) Reduction of infectious yield of EBOV-ZsG (left panel) and NiV-ZsG (middle panel) by RDV and ODBG-P-RVn in HSAEC1-KT cells. Compound cytotoxicity/cell viability (right panel) in HSAEC1-KT cells measured via CellTiterGlo 2.0 assay. Dose-response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point, 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 or 4 biological replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate. Infectious yield reduction assays were conducted once with biological quadruplicates.</p>
</caption>
<graphic xlink:href="EMS132549-f002"/>
</fig>
<table-wrap id="T1" position="float" orientation="landscape">
<label>Table 1</label>
<caption>
<title>Mean antiviral activity of RVn, RDV, and ODBG-P-RVn in Vero E6, Huh7, and NCI-H358 cell lines</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="center" valign="middle" rowspan="2" colspan="4" style="border-top:hidden;border-left:hidden"> </th>
<th align="center" valign="middle" colspan="9">Vero E6</th>
<th align="center" valign="middle" colspan="9">
<styled-content style="font-size:15px;color:#ff0000">Huh7</styled-content>/<styled-content style="font-size:15px;color:#4471c4">NCI-H358</styled-content>
</th>
</tr>
<tr>
<th align="center" valign="middle" colspan="3">RVn (GS-441524)</th>
<th align="center" valign="middle" colspan="3">RDV (GS-5734)</th>
<th align="center" valign="middle" colspan="3">ODBG-P-RVn</th>
<th align="center" valign="middle" colspan="3">RVn (GS-441524)</th>
<th align="center" valign="middle" colspan="3">RDV (GS-5734)</th>
<th align="center" valign="middle" colspan="3">ODBG-P-RVn</th>
</tr>
<tr>
<th align="center" valign="middle">Virus Family</th>
<th align="center" valign="middle" style="border-right:hidden">Virus</th>
<th align="center" valign="middle">Species/Variant</th>
<th align="center" valign="middle">Assay</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: &gt;100)</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: &gt;100)</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: &gt;100)</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: &gt;<styled-content style="font-size:15px;color:#ff0000">100</styled-content>/&gt;<styled-content style="font-size:15px;color:#4471c4">100</styled-content>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>:<styled-content style="font-size:15px;color:#ff0000">54.2 ± 6.0</styled-content>/<styled-content style="font-size:15px;color:#4471c4">77.2 ± 5.3</styled-content>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>:<styled-content style="font-size:15px;color:#ff0000">93.4 ± 3.0</styled-content>/&gt;<styled-content style="font-size:15px;color:#4471c4">100</styled-content>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="2">
<italic>Filoviridae</italic>
</td>
<td align="center" valign="middle" style="border-right:hidden">EBOV</td>
<td align="center" valign="middle">Rec. Makona-ZsG</td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle" style="border-right:hidden">2.03 ± 0.50</td>
<td align="center" valign="middle" style="border-right:hidden">7.54 ± 1.09</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle" style="border-right:hidden">5.15 ± 1.09</td>
<td align="center" valign="middle" style="border-right:hidden">17.31 ± 0.89</td>
<td align="center" valign="middle">&gt;19</td>
<td align="center" valign="middle" style="border-right:hidden">0.39 ± 0.10</td>
<td align="center" valign="middle" style="border-right:hidden">1.71 ± 0.25</td>
<td align="center" valign="middle">&gt;258</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">1.84 ± 0.31</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">6.91 ± 1.79</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">&gt;54</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.020 ± 0.003</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.16 ± 0.02</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">2710</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.37 ± 0.06</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">2.13 ± 0.37</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">251</styled-content>
</td>
</tr>
<tr style="border-top: hidden">
<td align="center" valign="middle" style="border-right:hidden">MARV</td>
<td align="center" valign="middle">Rec. Bat371-ZsG</td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle" style="border-right:hidden">0.96 ± 0.09</td>
<td align="center" valign="middle" style="border-right:hidden">4.05 ± 1.42</td>
<td align="center" valign="middle">104</td>
<td align="center" valign="middle" style="border-right:hidden">2.16 ± 0.27</td>
<td align="center" valign="middle" style="border-right:hidden">10.22 ± 2.02</td>
<td align="center" valign="middle">&gt;46</td>
<td align="center" valign="middle" style="border-right:hidden">0.19 ± 0.04</td>
<td align="center" valign="middle" style="border-right:hidden">0.81 ± 0.12</td>
<td align="center" valign="middle">&gt;521</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">1.92 ± 0.06</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">4.47 ± 0.48</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">&gt;52</styled-content>
</td>
<td align="center" valign="middle" colspan="2" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.025 ± 0.0020.075 ± 0.003</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">2128</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.33 ± 0.02</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.99 ± 0.09</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">285</styled-content>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="8">
<italic>Paramxyovirdae</italic>
</td>
<td align="center" valign="middle" style="border-right:hidden">NiV-M</td>
<td align="center" valign="middle">Rec. Malaysia-ZsG</td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle" style="border-right:hidden">1.10 ± 0.40</td>
<td align="center" valign="middle" style="border-right:hidden">2.20 ± 1.05</td>
<td align="center" valign="middle">73</td>
<td align="center" valign="middle" style="border-right:hidden">5.87 ± 0.19</td>
<td align="center" valign="middle" style="border-right:hidden">9.82 ± 0.43</td>
<td align="center" valign="middle">&gt;16</td>
<td align="center" valign="middle" style="border-right:hidden">0.31 ± 0.04</td>
<td align="center" valign="middle" style="border-right:hidden">0.78 ± 0.28</td>
<td align="center" valign="middle">&gt;196</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">2.43 ± 0.31</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">5.95 ± 1.10</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;41</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.075 ± 0.001</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.31 ± 0.04</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">1026</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.50 ± 0.06</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">2.83 ± 1.39</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;198</styled-content>
</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle">CPE</td>
<td align="center" valign="middle" style="border-right:hidden">0.48 ± 0.06</td>
<td align="center" valign="middle" style="border-right:hidden">0.78 ± 0.19</td>
<td align="center" valign="middle">207</td>
<td align="center" valign="middle" style="border-right:hidden">3.34 ± 0.34</td>
<td align="center" valign="middle" style="border-right:hidden">5.39 ± 0.29</td>
<td align="center" valign="middle">&gt;30</td>
<td align="center" valign="middle" style="border-right:hidden">0.19 ± 0.01</td>
<td align="center" valign="middle" style="border-right:hidden">0.30 ± 0.04</td>
<td align="center" valign="middle">&gt;522</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle">N/A</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">NiV-B</td>
<td align="center" valign="middle">Bangladesh</td>
<td align="center" valign="middle">CPE</td>
<td align="center" valign="middle" style="border-right:hidden">0.52 ± 0.02</td>
<td align="center" valign="middle" style="border-right:hidden">1.14 ± 0.02</td>
<td align="center" valign="middle">192</td>
<td align="center" valign="middle" style="border-right:hidden">2.84 ± 0.10</td>
<td align="center" valign="middle" style="border-right:hidden">5.81 ± 0.44</td>
<td align="center" valign="middle">&gt;35</td>
<td align="center" valign="middle" style="border-right:hidden">0.17 ± 0.01</td>
<td align="center" valign="middle" style="border-right:hidden">0.38 ± 0.04</td>
<td align="center" valign="middle">&gt;599</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">3.42 ± 0.005</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">5.41 ± 0.29</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;29</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.12 ± 0.0004</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.19 ± 0.01</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">661</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.82 ± 0.053</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">1.38 ± 0.05</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;122</styled-content>
</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">HeV</td>
<td align="center" valign="middle">1996</td>
<td align="center" valign="middle">CPE</td>
<td align="center" valign="middle" style="border-right:hidden">1.43 ± 0.17</td>
<td align="center" valign="middle" style="border-right:hidden">12.06 ± 3.14</td>
<td align="center" valign="middle">70</td>
<td align="center" valign="middle" style="border-right:hidden">4.56 ± 0.20</td>
<td align="center" valign="middle" style="border-right:hidden">17.58 ± 3.91</td>
<td align="center" valign="middle">&gt;22</td>
<td align="center" valign="middle" style="border-right:hidden">0.37 ± 0.04</td>
<td align="center" valign="middle" style="border-right:hidden">3.93 ± 1.98</td>
<td align="center" valign="middle">&gt;270</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">3.68 ± 0.08</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">6.33 ± 0.18</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;27</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.16 ± 0.02</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.25 ± 0.03</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">491</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.95 ± 0.12</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">1.42 ± 0.03</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;105</styled-content>
</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">MV</td>
<td align="center" valign="middle">Rec. rMV<sup>EZ</sup>GFP(3)</td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle" style="border-right:hidden">0.58 ± 0.20</td>
<td align="center" valign="middle" style="border-right:hidden">1.71 ± 0.07</td>
<td align="center" valign="middle">172</td>
<td align="center" valign="middle" style="border-right:hidden">4.97 ± 0.25</td>
<td align="center" valign="middle" style="border-right:hidden">6.12 ± 0.3</td>
<td align="center" valign="middle">&gt;20</td>
<td align="center" valign="middle" style="border-right:hidden">0.16 ± 0.03</td>
<td align="center" valign="middle" style="border-right:hidden">0.21 ± 0.01</td>
<td align="center" valign="middle">&gt;609</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.88 ± 0.16</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">6.99 ± 1.90</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;113</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.025 ± 0.007</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.13 ± 0.09</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">3074</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.12 ± 0.003</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.86 ± 0.22</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;803</styled-content>
</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">hPIV3</td>
<td align="center" valign="middle">Rec. JS-GFP</td>
<td align="center" valign="middle">FFU</td>
<td align="center" valign="middle" style="border-right:hidden">0.14 ± 0.01</td>
<td align="center" valign="middle" style="border-right:hidden">0.28 ± 0.02</td>
<td align="center" valign="middle">70</td>
<td align="center" valign="middle" style="border-right:hidden">0.43 ± 0.09</td>
<td align="center" valign="middle" style="border-right:hidden">0.90 ± 0.03</td>
<td align="center" valign="middle">&gt;232</td>
<td align="center" valign="middle" colspan="2" style="border-right:hidden">0.026 ± 0.0020.050 ± 0.002</td>
<td align="center" valign="middle">&gt;3896</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">1.43 ± 0.16</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">1.98 ± 0.05</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;70</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.031 ± 0.002</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.052 ± 0.01</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">2458</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.22 ± 0.01</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#4471c4">0.43 ± 0.02</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;457</styled-content>
</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">MuV</td>
<td align="center" valign="middle">Rec. IA2006-eGFP</td>
<td align="center" valign="middle">FFU</td>
<td align="center" valign="middle" style="border-right:hidden">5.11 ± 0.20</td>
<td align="center" valign="middle" style="border-right:hidden">7.80 ± 0.64</td>
<td align="center" valign="middle">18</td>
<td align="center" valign="middle" style="border-right:hidden">16.81 ± 1.23</td>
<td align="center" valign="middle" style="border-right:hidden">25.1 ± 1.97</td>
<td align="center" valign="middle">&gt;4.9</td>
<td align="center" valign="middle" style="border-right:hidden">1.13 ± 0.04</td>
<td align="center" valign="middle" style="border-right:hidden">2.53 ± 0.25</td>
<td align="center" valign="middle">&gt;56</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">9.3 ± 0.30</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">13.71 ± 0.24</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">&gt;11</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.20 ± 0.003</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.24 ± 0.003</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">266</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">1.85 ± 0.11</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">2.24 ± 0.23</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">50</styled-content>
</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">SoSuV</td>
<td align="center" valign="middle">Rec. 2012-ZsG</td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle" style="border-right:hidden">1.00 ± 0.10</td>
<td align="center" valign="middle" style="border-right:hidden">2.72 ± 0.62</td>
<td align="center" valign="middle">100</td>
<td align="center" valign="middle" style="border-right:hidden">5.31 ± 1.8</td>
<td align="center" valign="middle" style="border-right:hidden">19.10 ± 9.31</td>
<td align="center" valign="middle">&gt;19</td>
<td align="center" valign="middle" style="border-right:hidden">0.31 ± 0.089</td>
<td align="center" valign="middle" style="border-right:hidden">0.80 ± 0.06</td>
<td align="center" valign="middle">&gt;325</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">2.06 ± 0.09</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">7.76 ± 1.11</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">&gt;48</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.052 ± 0.01</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.13 ± 0.02</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">1042</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">0.52 ± 0.10</styled-content>
</td>
<td align="center" valign="middle" style="border-right:hidden">
<styled-content style="font-size:15px;color:#ff0000">1.08 ± 0.15</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">180</styled-content>
</td>
</tr>
<tr>
<td align="center" valign="middle">
<italic>Pneumoviridae</italic>
</td>
<td align="center" valign="middle">RSV</td>
<td align="center" valign="middle">Rec. rgRSV0224 (A2)</td>
<td align="center" valign="middle">FFU</td>
<td align="center" valign="middle">0.49 ± 0.05</td>
<td align="center" valign="middle">0.62 ± 0.01</td>
<td align="center" valign="middle">206</td>
<td align="center" valign="middle">1.80 ± 0.08</td>
<td align="center" valign="middle">2.40 ± 0.27</td>
<td align="center" valign="middle">&gt;55</td>
<td align="center" valign="middle">0.10 ± 0.02</td>
<td align="center" valign="middle">0.22 ± 0.03</td>
<td align="center" valign="middle">&gt;997</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">1.93 ± 0.02</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">2.36 ± 0.08</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;51</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">0.078 ± 0.004</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">0.17 ± 0.02</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">991</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">0.55 ± 0.057</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">1.41 ± 0.09</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#4471c4">&gt;180</styled-content>
</td>
</tr>
<tr>
<td align="center" valign="middle">
<italic>Coronaviridae</italic>
</td>
<td align="center" valign="middle">SARS-CoV-2</td>
<td align="center" valign="middle">Rec. icSARS-CoV-2 mNG (WA1)</td>
<td align="center" valign="middle">FFU</td>
<td align="center" valign="middle">0.42 ± 0.09</td>
<td align="center" valign="middle">0.60 ± 0.06</td>
<td align="center" valign="middle">236</td>
<td align="center" valign="middle">1.77 ± 0.13</td>
<td align="center" valign="middle">2.81 ± 0.78</td>
<td align="center" valign="middle">&gt;56</td>
<td align="center" valign="middle">0.10 ± 0.005</td>
<td align="center" valign="middle">0.16 ± 0.01</td>
<td align="center" valign="middle">&gt;997</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">0.69 ± 0.01</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">1.50 ± 0.20</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">&gt;144</styled-content>
</td>
<td align="center" valign="middle" colspan="2">
<styled-content style="font-size:15px;color:#ff0000">0.011 ± 0.0010.035 ± 0.002</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">5073</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">0.12 ± 0.02</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">0.69 ± 0.07</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">778</styled-content>
</td>
</tr>
<tr>
<td align="center" valign="middle">
<italic>Flaviviridae</italic>
</td>
<td align="center" valign="middle">YFV</td>
<td align="center" valign="middle">17D</td>
<td align="center" valign="middle">CPE</td>
<td align="center" valign="middle">3.52 ± 0.24</td>
<td align="center" valign="middle">30.25 ± 10.08</td>
<td align="center" valign="middle">28</td>
<td align="center" valign="middle">19.86 ± 1.73</td>
<td align="center" valign="middle">&gt;50</td>
<td align="center" valign="middle">&gt;5</td>
<td align="center" valign="middle">0.87 ± 0.043</td>
<td align="center" valign="middle">7.37 ± 1.59</td>
<td align="center" valign="middle">&gt;114</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">36.83 ± 2.85</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">&gt;50</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">&gt;2.7</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">0.88 ± 0.057</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">3.09 ± 1.47</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">62</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">14.11 ± 0.90</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">&gt;50</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">6.6</styled-content>
</td>
</tr>
<tr>
<td align="center" valign="middle">
<italic>Arenaviridae</italic>
</td>
<td align="center" valign="middle">LASV</td>
<td align="center" valign="middle">Rec. Josiah-ZsG</td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">31.14 ± 7.79</td>
<td align="center" valign="middle">&gt;50</td>
<td align="center" valign="middle">&gt;3</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">N/A</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">2.87 ± 0.61</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">5.17 ± 0.33</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">19</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">N/A</styled-content>
</td>
</tr>
<tr>
<td align="center" valign="middle">
<italic>Nairoviridae</italic>
</td>
<td align="center" valign="middle">CCHF</td>
<td align="center" valign="middle">Rec. IbAr10200-ZsG</td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">NI</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">N/A</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">N/A</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">NI</styled-content>
</td>
<td align="center" valign="middle">
<styled-content style="font-size:15px;color:#ff0000">N/A</styled-content>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<p id="P6">EC<sub>50</sub>, 50% effective inhibition concentration; EC<sub>90</sub>, 90% effective inhibition concentration; CC<sub>50</sub>, 50% cytotoxic concentration; SI, selective index = EC<sub>50</sub>/CC<sub>50</sub>; REP, reporter; CPE, cytopathic effect; FFU, focus-forming unit; ND, not determined; NI, no inhibition; N/A, not applicable; Rec, recombinant. Mean values with ± standard deviation values were derived from 3 independent experiments performed in biological triplicates except for NiV-B (NCI-H358), HeV (NCI-H358), and YFV (Vero E6)which were performed twice in biological triplicates. Data in red text derived from Huh7 cells, data in blue derived from NCI-H358 cells. REP/FFU/CPE assays were conducted between 72-144 hpi. EC<sub>50</sub>, EC<sub>90</sub>, and CC<sub>50</sub> values were calculated using Graphpad Prism 9 software.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float" orientation="landscape">
<label>Table 2</label>
<caption>
<title>Mean antiviral activity of RVn, RDV, and ODBG-P-RVn in primary-like hTERT-immortalized microvascular endothelial (TIME) and small airway epithelial (HSAEC1-KT) cell lines</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="center" valign="middle" rowspan="2" colspan="4" style="border-top:hidden;border-left:hidden"> </th>
<th align="center" valign="middle" colspan="9">HSAEC1-KT</th>
<th align="center" valign="middle" colspan="9">TIME</th>
</tr>
<tr>
<th align="center" valign="middle" colspan="3">RVn (GS-441524)</th>
<th align="center" valign="middle" colspan="3">RDV (GS-5734)</th>
<th align="center" valign="middle" colspan="3">ODBG-P-RVn</th>
<th align="center" valign="middle" colspan="3">RVn (GS-441524)</th>
<th align="center" valign="middle" colspan="3">RDV (GS-5734)</th>
<th align="center" valign="middle" colspan="3">ODBG-P-RVn</th>
</tr>
<tr>
<th align="center" valign="middle">Virus Family</th>
<th align="center" valign="middle" style="border-right:hidden">Virus</th>
<th align="center" valign="middle">Species/Variant</th>
<th align="center" valign="middle">Assay</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: &gt;100)</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: &gt;100)</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: 20.5 ± 0.29)</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: &gt;100)</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: 17.2 ± 0.42)</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>50</sub>
</th>
<th align="center" valign="middle" style="border-right:hidden">EC<sub>90</sub>
</th>
<th align="center" valign="middle">SI (CC<sub>50</sub>: &gt;50)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="3">
<italic>Filoviridae</italic>
</td>
<td align="center" valign="middle" style="border-right:hidden">EBOV</td>
<td align="center" valign="middle">Rec. Makona-ZsG</td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle" style="border-right:hidden">10.7 ± 2.62</td>
<td align="center" valign="middle" style="border-right:hidden">21.79 ± 3.16</td>
<td align="center" valign="middle">&gt;9.3</td>
<td align="center" valign="middle" style="border-right:hidden">0.17 ± 0.02</td>
<td align="center" valign="middle" style="border-right:hidden">0.41 ± 0.14</td>
<td align="center" valign="middle">&gt;587</td>
<td align="center" valign="middle" style="border-right:hidden">0.21 ± 0.02</td>
<td align="center" valign="middle" style="border-right:hidden">1.06 ± 0.18</td>
<td align="center" valign="middle">98</td>
<td align="center" valign="middle" style="border-right:hidden">14.88 ± 0.28</td>
<td align="center" valign="middle" style="border-right:hidden">17.24 ± 0.16</td>
<td align="center" valign="middle">&gt;3.36</td>
<td align="center" valign="middle" style="border-right:hidden">0.13 ± 0.04</td>
<td align="center" valign="middle" style="border-right:hidden">0.2 ± 0.01</td>
<td align="center" valign="middle">132</td>
<td align="center" valign="middle" style="border-right:hidden">0.99 ± 0.063</td>
<td align="center" valign="middle" style="border-right:hidden">1.96 ± 0.043</td>
<td align="center" valign="middle">&gt;50</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle">VTR</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle" style="border-right:hidden">0.11</td>
<td align="center" valign="middle" style="border-right:hidden">0.82</td>
<td align="center" valign="middle">&gt;909</td>
<td align="center" valign="middle" style="border-right:hidden">0.21</td>
<td align="center" valign="middle" style="border-right:hidden">0.95</td>
<td align="center" valign="middle">98</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle" style="border-right:hidden">0.032</td>
<td align="center" valign="middle" style="border-right:hidden">0.064</td>
<td align="center" valign="middle">530</td>
<td align="center" valign="middle" style="border-right:hidden">0.15</td>
<td align="center" valign="middle" style="border-right:hidden">0.39</td>
<td align="center" valign="middle">&gt;324</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">MARV</td>
<td align="center" valign="middle">Rec. Bat371-ZsG</td>
<td align="center" valign="middle">REP/FFU</td>
<td align="center" valign="middle" style="border-right:hidden">35.53 ± 7.07</td>
<td align="center" valign="middle" style="border-right:hidden">71.35 ± 1.28</td>
<td align="center" valign="middle">&gt;2.8</td>
<td align="center" valign="middle" style="border-right:hidden">0.75 ± 0.19</td>
<td align="center" valign="middle" style="border-right:hidden">2.92 ± 0.14</td>
<td align="center" valign="middle">&gt;133</td>
<td align="center" valign="middle" style="border-right:hidden">0.71 ± 0.11</td>
<td align="center" valign="middle" style="border-right:hidden">3.67 ± 0.49</td>
<td align="center" valign="middle">29</td>
<td align="center" valign="middle" style="border-right:hidden">5.2 ± 0.26</td>
<td align="center" valign="middle" style="border-right:hidden">6.89 ± 0.86</td>
<td align="center" valign="middle">&gt;9.61</td>
<td align="center" valign="middle" style="border-right:hidden">0.04 ± 0.003</td>
<td align="center" valign="middle" style="border-right:hidden">0.086 ± 0.004</td>
<td align="center" valign="middle">430</td>
<td align="center" valign="middle" style="border-right:hidden">0.23 ± 0.036</td>
<td align="center" valign="middle" style="border-right:hidden">0.66 ± 0.032</td>
<td align="center" valign="middle">&gt;213</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="7">
<italic>Paramxyovirdae</italic>
</td>
<td align="center" valign="middle" style="border-right:hidden"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle" style="border-right:hidden">16.46 ± 0.04</td>
<td align="center" valign="middle" style="border-right:hidden">19.12 ± 0.05</td>
<td align="center" valign="middle">&gt;6.1</td>
<td align="center" valign="middle" style="border-right:hidden">0.23 ± 0.01</td>
<td align="center" valign="middle" style="border-right:hidden">0.31 ± 0.06</td>
<td align="center" valign="middle">&gt;440</td>
<td align="center" valign="middle" style="border-right:hidden">0.57 ± 0.013</td>
<td align="center" valign="middle" style="border-right:hidden">0.97 ± 0.21</td>
<td align="center" valign="middle">36</td>
<td align="center" valign="middle" style="border-right:hidden">13.53 ± 2.44</td>
<td align="center" valign="middle" style="border-right:hidden">17.52 ± 0.77</td>
<td align="center" valign="middle">&gt;3.70</td>
<td align="center" valign="middle" style="border-right:hidden">0.10 ± 0.01</td>
<td align="center" valign="middle" style="border-right:hidden">0.20 ± 0.01</td>
<td align="center" valign="middle">172</td>
<td align="center" valign="middle" style="border-right:hidden">0.75 ± 0.05</td>
<td align="center" valign="middle" style="border-right:hidden">2.01 ± 0.30</td>
<td align="center" valign="middle">&gt;66</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden;border-bottom:hidden">NiV-M</td>
<td align="center" valign="middle" style="border-bottom:hidden">Rec. Malaysia-ZsG</td>
<td align="center" valign="middle" style="border-bottom:hidden">CPE</td>
<td align="center" valign="middle" style="border-right:hidden;border-bottom:hidden">16.12 ± 4.21</td>
<td align="center" valign="middle" style="border-right:hidden;border-bottom:hidden">78.1 ± 35.08</td>
<td align="center" valign="middle" style="border-bottom:hidden">&gt;6.2</td>
<td align="center" valign="middle" style="border-right:hidden;border-bottom:hidden">0.31 ± 0.04</td>
<td align="center" valign="middle" style="border-right:hidden;border-bottom:hidden">0.075 ± 0.004</td>
<td align="center" valign="middle" style="border-bottom:hidden">&gt;318</td>
<td align="center" valign="middle" style="border-right:hidden;border-bottom:hidden">0.90 ± 0.07</td>
<td align="center" valign="middle" style="border-right:hidden;border-bottom:hidden">10.22 ± 4.99</td>
<td align="center" valign="middle" style="border-bottom:hidden">23</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle" style="border-right:hidden">0.054</td>
<td align="center" valign="middle" style="border-right:hidden">0.07</td>
<td align="center" valign="middle">319</td>
<td align="center" valign="middle" style="border-right:hidden">0.26</td>
<td align="center" valign="middle" style="border-right:hidden">0.77</td>
<td align="center" valign="middle">&gt;195</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-right:hidden"/>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle">VTR</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle" style="border-right:hidden">ND</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle" style="border-right:hidden">0.26</td>
<td align="center" valign="middle" style="border-right:hidden">0.36</td>
<td align="center" valign="middle">&gt;379</td>
<td align="center" valign="middle" style="border-right:hidden">0.47</td>
<td align="center" valign="middle" style="border-right:hidden">0.77</td>
<td align="center" valign="middle">44</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">NiV-B</td>
<td align="center" valign="middle">Bangladesh</td>
<td align="center" valign="middle">CPE</td>
<td align="center" valign="middle" style="border-right:hidden">11.23 ± 0.63</td>
<td align="center" valign="middle" style="border-right:hidden">33.6 ± 1.58</td>
<td align="center" valign="middle">&gt;8.9</td>
<td align="center" valign="middle" style="border-right:hidden">0.21 ± 0.063</td>
<td align="center" valign="middle" style="border-right:hidden">0.62 ± 0.20</td>
<td align="center" valign="middle">&gt;379</td>
<td align="center" valign="middle" style="border-right:hidden">0.41 ± 0.039</td>
<td align="center" valign="middle" style="border-right:hidden">1.71 ± 0.66</td>
<td align="center" valign="middle">50</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">HeV</td>
<td align="center" valign="middle">1994</td>
<td align="center" valign="middle">CPE</td>
<td align="center" valign="middle" style="border-right:hidden">11.52 ± 1.49</td>
<td align="center" valign="middle" style="border-right:hidden">26.11 ± 4.44</td>
<td align="center" valign="middle">&gt;8.7</td>
<td align="center" valign="middle" style="border-right:hidden">0.22 ± 0.04</td>
<td align="center" valign="middle" style="border-right:hidden">0.65 ± 0.11</td>
<td align="center" valign="middle">&gt;463</td>
<td align="center" valign="middle" style="border-right:hidden">0.42 ± 0.023</td>
<td align="center" valign="middle" style="border-right:hidden">1.19 ± 0.061</td>
<td align="center" valign="middle">49</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">MV</td>
<td align="center" valign="middle">Rec. rMV<sup>EZ</sup>GFP(3)</td>
<td align="center" valign="middle">REP</td>
<td align="center" valign="middle" style="border-right:hidden">4.98 ± 0.37</td>
<td align="center" valign="middle" style="border-right:hidden">12.02 ± 2.7</td>
<td align="center" valign="middle">&gt;20</td>
<td align="center" valign="middle" style="border-right:hidden">0.063 ± 0.02</td>
<td align="center" valign="middle" style="border-right:hidden">0.128 ± 0.016</td>
<td align="center" valign="middle">&gt;1587</td>
<td align="center" valign="middle" style="border-right:hidden">0.082 ± 0.026</td>
<td align="center" valign="middle" style="border-right:hidden">0.29 ± 0.043</td>
<td align="center" valign="middle">251</td>
</tr>
<tr style="border-top:hidden">
<td align="center" valign="middle" style="border-right:hidden">hPIV3</td>
<td align="center" valign="middle">Rec. JS-GFP</td>
<td align="center" valign="middle">FFU</td>
<td align="center" valign="middle" style="border-right:hidden">4.96 ± 0.05</td>
<td align="center" valign="middle" style="border-right:hidden">5.77 ± 0.06</td>
<td align="center" valign="middle">&gt;20</td>
<td align="center" valign="middle" colspan="2" style="border-right:hidden">0.063 ± 0.0010.074 ± 0.002</td>
<td align="center" valign="middle">&gt;1582</td>
<td align="center" valign="middle" style="border-right:hidden">0.091 ± 0.009</td>
<td align="center" valign="middle" style="border-right:hidden">0.20 ± 0.008</td>
<td align="center" valign="middle">226</td>
</tr>
<tr>
<td align="center" valign="middle">
<italic>Pneumoviridae</italic>
</td>
<td align="center" valign="middle">RSV</td>
<td align="center" valign="middle">Rec. rgRSV0224 (A2)</td>
<td align="center" valign="middle">FFU</td>
<td align="center" valign="middle" style="border-right:hidden">4.92 ± 0.47</td>
<td align="center" valign="middle" style="border-right:hidden">8.09 ± 0.68</td>
<td align="center" valign="middle">&gt;20</td>
<td align="center" valign="middle" style="border-right:hidden">0.088 ± 0.026</td>
<td align="center" valign="middle" style="border-right:hidden">0.21 ± 0.033</td>
<td align="center" valign="middle">&gt;1134</td>
<td align="center" valign="middle" style="border-right:hidden">0.12 ± 0.008</td>
<td align="center" valign="middle" style="border-right:hidden">0.34 ± 0.047</td>
<td align="center" valign="middle">176</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN2">
<p id="P7">EC<sub>50</sub>, 50% effective inhibition concentration; EC<sub>90</sub>, 90% effective inhibition concentration; CC<sub>50</sub>, 50% cytotoxic concentration; SI, selective index = EC<sub>50</sub>/CC<sub>50</sub>; REP, reporter; CPE, cytopathic effect; FFU, focus-forming unit; VTR, virus titer reduction; ND, not determined; N/A, not applicable; Rec, recombinant. Mean values with ± standard deviation values were derived from a minimum of 3 independent experiments performed in biological triplicates. REP/FFU/CPE/VTR assays were conducted at 72 hpi. EC <sub>50</sub>, EC<sub>90</sub>, and CC<sub>50</sub> values were calculated using Graphpad Prism 9 software.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
